Thursday, October 9, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Recommendations and Price Targets for Brunswick March 8 2024

Elaine Mendonca by Elaine Mendonca
March 8, 2024
in Breaking News
0
Finances-and-tech
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Analyst Recommendations for Brunswick as of March 8, 2024

In the past three months, Brunswick (NYSE: BC) has received ratings from 7 analysts, showcasing a variety of sentiments ranging from bullish to bearish. Here is a breakdown of their recent ratings and insights:

Total Ratings:
– Bullish: 6
– Indifferent: 1
– Somewhat Bullish, Somewhat Bearish, Bearish: 0

Recent Changes in Ratings:
– Last 30 Days:
– Bullish: 1
– Other Ratings: 0
– 1 Month Ago:
– Bullish: 1
– Other Ratings: 0
– 2 Months Ago:
– Bullish: 4
– Other Ratings: 0
– 3 Months Ago:
– Indifferent: 1

Price Targets:
– Average Target: $105.71
– High Estimate: $115.00
– Low Estimate: $94.00
– Average Increase from Previous Target: 10.69%

Key Analyst Actions and Insights:
Analysts have recently made significant adjustments to their ratings and price targets for Brunswick. Here are some key actions taken by analysts:

– Anna Glaessgen from Jefferies raised the Buy rating with a current price target of $115.00, up from $95.00.
– Eric Wold from B. Riley Securities also raised the Buy rating with a current price target of $108.00, compared to the prior target of $100.00.
– Michael Swartz from Truist Securities lowered the Buy rating to $105.00 from $115.00.
– Scott Stember Roth from MKM raised the Buy rating to $94.00 from $85.00.
– Drew Crum from Stifel raised the Buy rating to $97.00 from $88.00.
– Michael Swartz from Truist Securities raised the Buy rating to $115.00 from $90.00.
– Eric Wold from B. Riley Securities announced a Neutral rating with a price target of $106.00.

These actions highlight the ever-changing landscape of analyst responses to market fluctuations and company performance, offering valuable insights into Brunswick’s current position.

For more in-depth forecasts and analyst predictions, consider consulting TipRanks and other financial platforms such as WSJ and Benzinga.

BC Stock Shows Strong Performance on March 8, 2024: Trading Near 52-Week High and Above 200-Day Moving Average

On March 8, 2024, BC stock showed strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. The price of BC shares increased by $2.06 since the market last closed, marking a 2.30% rise. The stock opened at $90.94, which was $1.39 higher than its previous close, indicating positive price momentum. Investors are optimistic about BC’s future prospects as it is trading near the top of its 52-week range. BC trading above the 200-day simple moving average is a positive sign for its overall performance. Investors will be watching closely to see if BC can continue its upward trajectory.

BC Stock Performance Analysis: Total Revenue, Net Income, and EPS Decline on March 8, 2024

On March 8, 2024, BC stock’s performance was closely scrutinized by investors and analysts. The company’s total revenue for the past year was reported at $6.40 billion, with a decrease of 6.03% compared to the previous year. The total revenue for the last quarter was $1.36 billion, which remained flat compared to the previous quarter.

Similarly, BC’s net income for the past year was $420.40 million, showing a decrease of 37.9% compared to the previous year. The net income for the last quarter was $71.00 million, which also remained flat compared to the previous quarter.

Earnings per share (EPS) for BC stock were reported at $5.96 for the past year, indicating a decrease of 33.76% compared to the previous year. The EPS for the last quarter was $0.88, showing a significant decrease of 45.16% compared to the previous quarter.

Overall, BC stock’s performance on March 8, 2024, was not particularly impressive, with decreases in total revenue, net income, and earnings per share compared to the previous year and quarter. Investors and analysts will be closely monitoring the company’s future financial performance to assess its long-term sustainability and growth prospects.

Tags: BC
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Renewable energy

Analysts Perspectives on Maxeon Solar Technologies A Shift Towards Negativity

COST stock news

Analysts Provide Mixed Views on Marvell Technology Incs Performance

Renewable energy

Analyzing Short Interest in SolarEdge Technologies and Its Industry Peers

Recommended

EEFT stock news

Analyst Maintains Neutral Rating on FMC with Adjusted Price Target

2 years ago
Intel Stock

Intel’s Remarkable Resurgence: Strategic Alliances Fuel Turnaround Hopes

2 weeks ago
Micron Stock

Market Experts Rally Behind Micron as Stock Reaction Defies Expectations

1 day ago
G III Apparel Stock

G-III Apparel’s Pivotal Quarter: High Stakes and High Hopes

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

3M Considers Major Business Unit Divestment in Strategic Overhaul

Bristol-Myers Squibb’s Alzheimer’s Therapy Gains Momentum as Investors Weigh Pipeline Against Patent Cliff

Semiconductor Giant Navigates Geopolitical Crosscurrents

Security Concerns Rattle Palantir Investors Following Military Report

Apple Leadership Transition Gains Momentum as Successor Emerges

Alphabet’s AI Ambitions Face Critical Earnings Test

Trending

Microvast Holdings Stock
Automotive & E-Mobility

Microvast Shares Pause After Impressive Rally

by Felix Baarz
October 9, 2025
0

Microvast Holdings (MVST) shares experienced a modest pullback in recent trading, declining 0.78% to settle at $4.51....

Tesla Stock

Tesla’s Pricing Gambit Faces Market Scrutiny

October 9, 2025
McDonald's Stock

McDonald’s Pursues Turnaround Amid Legal Victory and AI Push

October 9, 2025
3M Stock

3M Considers Major Business Unit Divestment in Strategic Overhaul

October 9, 2025
Bristol-Myers Squibb Stock

Bristol-Myers Squibb’s Alzheimer’s Therapy Gains Momentum as Investors Weigh Pipeline Against Patent Cliff

October 9, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Microvast Shares Pause After Impressive Rally
  • Tesla’s Pricing Gambit Faces Market Scrutiny
  • McDonald’s Pursues Turnaround Amid Legal Victory and AI Push

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com